QUANTUM-SI INC. overview

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the highlights of an Investor & Analyst event that was hosted in New York City on November 20 th , 2024. Quantum-Si’s Management team announced Platinum™ Pro, the Company’s evolution of Platinum, as well as Proteus™, the Company’s new cutting-edge proteomics platform of the future, that is now under development. “We are very excited to have this...

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, has announced a distribution agreement with Avantor ® (NYSE: AVTR), a global leader in mission-critical products and services for the life sciences and advanced technology industries. Through this collaboration, Avantor will distribute Quantum-Si's Next-Generation Protein Sequencing (NGPS) portfolio, providing researchers across all market segments in the U.S. and Canada...

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced a collaboration with NVIDIA to develop its new proteomics platform, Proteus™, and advance Quantum-Si’s core technologies of amino acid binders and aminopeptidases using NVIDIA AI and accelerated computing. This collaboration aims to significantly enhance data processing speeds to handle the increased data volume from Proteus. By leveraging NVIDIA...

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™ and SkyWaterTechnology (NASDAQ: SKYT), the trusted technology realization partner, announced today they will jointly expand their relationship to support development of Proteus™, Quantum-Si’s next-generation platform designed to transform proteomic research. The expanded collaboration will develop the consumable for Proteus that will enable simultaneous large factor,...

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, and Planet Innovation today announced that they will partner on the development and manufacturing of Quantum-Si’s novel proteomics platform, Proteus™. Planet Innovation has a team of over four hundred people with expertise across design, development and manufacturing of scientific instrumentation and medical devices. Currently, Planet Innovation serves as the contract...

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that the Compensation Committee of Quantum-Si’s Board of Directors has granted 340,460 restricted stock units (“RSUs”) to a new employee under the Company’s previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the “2023 Inducement Plan”). The RSUs were granted as an inducement material to the new employee...

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it has been awarded Frost & Sullivan’s prestigious 2024 Technology Innovation Leadership Award in North America. This award recognizes QSI’s groundbreaking work in developing the Platinum ® instrument, the first benchtop sequencer capable of providing single-molecule resolution at the amino acid level, opening new frontiers for proteomic research....

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced financial results for the third quarter ended September 30, 2024. Press Release Highlights Reported revenue of $787,000 for the third quarter of 2024 Announced that Liberate Bio has integrated Platinum ® Next-Generation Sequencing into their platform for developing novel gene therapies with improved targeting capabilities Announced appointments of industry...